logo
AI rollout rattles Teleperformance, but some say the stock could double

AI rollout rattles Teleperformance, but some say the stock could double

CNBC09-07-2025
When CEO Daniel Julien took the stage in New York for a pivotal investors' relations day in June, he knew the stakes were high. Julien's company, the French outsourcing giant Teleperformance , had lost more than 75% of its value from its 2022 high. He was tasked with convincing his audience — investors and Wall Street analysts — that they had misunderstood the business. He, and other Teleperformance executives, spent the next three and a half hours explaining that AI was integral to the future of Teleperformance, citing "AI" more than 75 times. Teleperformance operates call centers and other business process outsourcing services. It is one of the largest employers in the world with nearly 500,000 workers worldwide. Julien's plan was detailed, and the targets were ambitious, yet the market's verdict was swift and brutal. Shares in the outsourcing firm tumbled 14% following the June 18 Capital Markets Day, when the company laid out its new AI-centric strategy. In the days that followed, the slide continued, wiping out nearly a fifth of the company's value. TEP-FR 1Y mountain The sell-off highlighted the market's doubts over the firm's future in an automated world, despite Julien's best efforts, even as a big acquisition in the sector suggested a premium for the very skills Teleperformance offers. Investment banks say that generative AI could pose both a major threat and opportunity for Teleperformance — a company built on the labor of hundreds of thousands of call-center agents. Executives at the CAC 40 company detailed plans to grow its core business with AI, setting long-term financial targets. The company is targeting 4% to 6% annual revenue growth by 2028, an adjusted profit margin of approximately 15.5%, and a cumulative net free cash flow (FCF) of approximately 3 billion euros ($3.5 billion) between 2026 and 2028. The company also earmarked roughly 1.5 billion euros for dividends and buybacks, another 600 million euros for AI-related investments, and the rest for paying down debt. The bear case For Wall Street's bears, the plan did little to reassure them about a business model under siege. Investors are worried about the deflationary pressure of AI. As automated systems handle more customer interactions, the value of traditional human-led services, particularly those in lower-cost offshore locations, comes under pressure. This is already starting to show. In 2024, the company's "Core Services" division saw its adjusted profit margin fall by 10% year-over-year, excluding one-time gains and expenses, on just 1.4% growth. "Into 2025 and beyond we are sceptical the company can meet consensus expectations as deflation from offshoring will likely persist, with automation-related deflation only set to accelerate," said JPMorgan analyst Sylvia Barker in a note to clients on July 7. Barker sees the stock rising just 3% to 91 euros by the end of next year. The 'Buy' side Bullish analysts, however, say that the sell-off is a significant overreaction, creating a compelling investment opportunity. For them, the market has priced in a worst-case scenario that ignores the company's ability to pivot and its financial strength. The 47-year-old company, founded by Julien, doubled its sales to more than 10 billion euros in 2024. It's also sitting on more than a billion euros of cash in its bank account, according to FactSet data, that it can deploy at will. Analysts at Berenberg, who have a Buy rating on Teleperformance, say it is "materially undervalued at 4x EBITDA," an adjusted profit metric. Bank of America, also with a Buy rating, called its valuation "attractive" and pointed to a shareholder-friendly capital return policy. Even some of the more cautious analysts acknowledge the low valuation. Nearly everyone, however, pointed to the lack of near-term guidance amid the start of heavy investments in AI as the reason behind the share tumble. "In our view, this is due to the company emphasising its heavy opex and capex investment in AI in the short term, alongside its hockey-stick trajectory growth to FY 2028," said Berenberg analyst Carl Raynsford in a note to clients on June 20. Raynsford — one of the most bullish analysts who expects the stock to more than double to 190 euros over the next 12 months — said the company's target of 3 billion euros of free cash flow by 2028 looks "overly cautious." These analysts believe the market is misinterpreting the company's AI investments. "We like the strategy," said Simona Sarli, analyst at Bank of America. "The company aims to expand into higher-growth back-office solutions and reposition its Customer Experience offering to high-value-added tasks via targeted AI investments." Peer review Adding to the complexity is a puzzling inconsistency in how the market is treating Teleperformance compared to its peers. Analysts at RBC Capital Markets highlighted that investors are "rewarding" Concentrix , a Nasdaq-listed peer, for its AI strategy, while writing off Teleperformance's equivalent as an "exercise in value destruction." RBC noted that Concentrix is up nearly 40% year-to-date, while Teleperformance is up just 8%, in line with France's CAC 40 index. TEP-FR CNXC YTD line They also point to a survey commissioned by Concentrix that showed that 85% of large companies expect to increase their outsourcing budgets over the next two to three years, with the "majority of that increase expected to be net new investments in supporting their AI agenda." Scotiabank echoed the sentiment on the sector. "Based on our ongoing discussions with global [customer experience (CX)] companies, we believe that, contrary to investor concerns, the revenue landscape for CX companies is not shrinking," said Scotiabank's Divya Goyal in a note to clients. "Instead, it is transitioning, with outsourcing on the rise. This propensity for outsourcing grows as new technologies are introduced into the market, ultimately benefiting established CX players." Capgemini's WNS acquisition Just as investors were weighing Teleperformance's AI strategy, the corporate M & A market delivered a powerful data point. On July 7, French IT consulting giant Capgemini announced it was acquiring WNS , a major player in the business process outsourcing (BPO) space, for $3.3 billion in cash. Capgemini has agreed to pay a 17% premium to the prior day's close at a valuation of 15 times forward earnings —a multiple nearly three times that of Teleperformance, analysts at TD Cowen pointed out. Crucially, the rationale for the premium price was WNS's perceived value in an AI-driven world, according to the analysts. "The deal counters certain market participants' bear thesis on BPM," said Bryan Bergin, TD Cowen's analyst. "Perception of BPO has been materially hampered amid the rise of GenAI/Agentic tech due to fears of cannibalization, though this has not yet happened broadly in practice yet." A 'show-me' story Caught between conflicting signals, many on Wall Street have adopted a wait-and-see approach, as captured by one analyst who said Teleperformance had become a "show-me story." "[Teleperformance's (TP)] new growth strategy needs to prove that AI can drive enough growth and sustainable new revenue streams to offset headwinds from the outright automation of some services, and accelerated deflation on others," said UBS analyst Nicole Manion in a note to clients. "While we note that TP has proven exactly this through previous tech shifts, the current rate of change means that it appears a much less certain outcome this time around," Manion added. Similarly, Bank of America's Sarli says the company has failed to buckle up investors who could be in for a rollercoaster ride over the next few years. "We don't doubt the merits and potential of the new strategy," Sarli said in a note to clients on June 24. "But we think management failed to reassure investors on whether progress to its 2028 financial targets will be linear or ... follow a year of transition in 2026, with the risk of potentially softer growth and margins than in 2025." Teleperformance did not respond to a request for comment from CNBC.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New tariffs could raise prices of Ozempic, Wegovy
New tariffs could raise prices of Ozempic, Wegovy

The Hill

time31 minutes ago

  • The Hill

New tariffs could raise prices of Ozempic, Wegovy

(NEXSTAR) – A trade deal between the U.S. and the European Union is expected to impose a 15% tax on pretty much all goods imported from Europe, from fancy French wines to sleek German cars and in-demand pharmaceuticals. Some of the most recognizable brand names that could be impacted include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to treat diabetes and promote weight loss. Both are made by Novo Nordisk, a Danish company. But the European drugs are extremely popular here in the U.S. Wegovy – the version of the drug that's FDA-approved to treat obesity – has about 200,000 weekly prescriptions in the U.S., according to Novo Nordisk. Even before the new tariffs, many people have found the medications to be prohibitively expensive. Without insurance, they cost about $500 a month. What is the Presidential Fitness Test? It's usually cheaper for those who can get the drug covered by their health plan. Novo says of its patients who have coverage in the U.S., 85% pay $25 or less per month. After the tariffs take effect, the prices of importing these medications into the U.S. will go up, but who will pay that tax isn't straightforward. Rena Conti, an associate professor at Boston University's Questrom School of Business, told NBC News that drug companies could just raise their price list right away to offset the higher cost. Those without insurance might notice the sticker price change, but those with coverage could end up paying more in higher premiums. 'The big picture is: The cost of imported drugs is about to become more expensive for all Americans,' Joe Brusuelas, principal and chief economist for RSM US, said in an interview with Axios. Other name-brand drugs like Botox, Viagra and Keytruda (a cancer medication) are also manufactured in Europe and impacted by the tariffs. Some drug generics were supposed to be carved out of the deal, but details were still pending as of Thursday. When asked how Ozempic and Wegovy would be impacted by the new 15% tariff, a Novo Nordisk spokesperson told Nexstar the company 'remains focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need.'

JPMorgan marks 1,000th branch opening since 2018 expansion plans
JPMorgan marks 1,000th branch opening since 2018 expansion plans

NBC News

timean hour ago

  • NBC News

JPMorgan marks 1,000th branch opening since 2018 expansion plans

JPMorgan Chase has built 1,000 new branches in seven years. That's more locations than most of its competitors operate in total. The bank is marking the milestone opening in Charlotte, North Carolina, on Thursday where Chairman and CEO Jamie Dimon is attending a ribbon-cutting ceremony. The firm has roughly 5,000 branches, the most of any American bank, according to Federal Reserve data from March. 'It's a great marker for us to be able to say, you can see our commitment over time and we're on a marathon with regard to this expansion,' said Jennifer Roberts, the CEO of Chase Consumer Banking, in an interview. 'A thousand [branches] is significant — a thousand is bigger than many regional competitors have at all.' In 2018, JPMorgan operated bank branches in 23 U.S. states and said it would expand into as many as 20 new markets over the following five years with about 400 new locations. By 2021, the firm said it had branches in all 48 lower states. And last February, JPMorgan announced a new, multibillion-dollar investment to open another 500 new locations by 2027. JPMorgan said over the past seven years, Chase has opened more bank branches than all of its large bank peers combined. However, many of JPMorgan's competitors have recently announced plans to expand their own footprints as the quest for deposits heats up. Bank of America recently announced a branch expansion, with plans to open 150 new centers by 2027. And Wells Fargo plans to add branches, especially now that it's fulfilled a regulatory consent order that had been constraining its growth. The industry-wide growth plans could help reverse a trend dating back to the 2008 financial crisis in which the U.S. has seen the net number of bank branches plummet. The combination of fewer overall banks and the advent of online banking has broadly made brick-and-mortar locations lower priority. However, in recent years, especially amid the population migration during and after the pandemic, banks have been reorienting their footprints to capture more deposits. Expanding in Charlotte puts JPMorgan head-to-head with rival Bank of America, which is headquartered there and has 71% market share in the city, according to KBW and S&P Global Market Intelligence data. Roberts said after this latest opening, Chase will have about 75 branches in North Carolina. She said that the bank is expanding there due to its 'young, fast-growing population' and that there's a 'lot of wealth coming into that area' as well. JPMorgan said at its investor day in May that its newer branches are expected to ultimately contribute more than $160 billion in incremental deposits. The firm said each new branch breaks even within four years. JPMorgan said when its expansion is complete, Chase will have added more than 1,100 branches, renovated 4,300 locations and entered 80 new markets. It also expects that 75% of the U.S. population will be able to reach one of its branches within an 'accessible drive.'

Reddit stock soars as company posts fastest quarterly revenue growth in 3 years
Reddit stock soars as company posts fastest quarterly revenue growth in 3 years

Yahoo

time2 hours ago

  • Yahoo

Reddit stock soars as company posts fastest quarterly revenue growth in 3 years

Reddit (RDDT) stock soared nearly 11% after the bell on Thursday as the social media platform reported second quarter revenue that surpassed Wall Street's expectations. The social media's revenue grew 78% to $500 million, its fastest revenue growth in three years, according to the company. That figure was ahead of the $425 million projected by Wall Street analysts tracked by Bloomberg. Reddit reported adjusted earnings per share of $0.92, ahead of the estimated $0.72. The company reported that global daily active users hit 110.4 million in the three months ended June 30, just above the 110 million expected by analysts, according to Bloomberg consensus data. Meanwhile, US daily active users hit 50.3 billion, slightly below the 50.5 million expected. Reddit also saw traction on its AI-powered search tool, Reddit Answers, which launched in December 2024 and had 6 million weekly active users in the second quarter, a jump from 1 million in the prior period. "Reddit is one of the few platforms positioned to become a true search destination," CEO Steve Huffman wrote in a letter to investors. In the past, investors have scrutinized Reddit's daily active user growth. Reddit shares sank following its quarterly reports in February and May despite earnings and revenue beating Wall Street's expectations. Changes to the Google (GOOG) Search algorithm created volatility in traffic to the site. Google accounts for 40% to 50% of Reddit's traffic, according to JPMorgan analyst Doug Anmuth, who holds a Neutral rating on the stock. Reddit shares have partly recovered losses from earlier in the year, climbing roughly 70% from the stock's low of about $87 in early April. The stock spiked in June after the company launched new AI ad tools for marketers at the Cannes Lions Festival. Still, Reddit trades far below the highs above $220 seen in February before its fourth quarter earnings report, and shares are down nearly 10% in 2025. Laura Bratton is a reporter for Yahoo Finance. Follow her on Bluesky @ Email her at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store